Feasibility Study: Ulthera System for the Treatment of Rosacea

Inclusion Criteria: * Male or female, aged 18 to 65 years. * Subject in good health. * Clinical diagnosis of Erythematotelangiectatic Rosacea. * Understands and accepts the obligation not to undergo any other procedures in the area(s) to be treated through the follow-up period. * Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. * Absence of physical or psychological conditions unacceptable to the investigator. * Willingness and ability to provide written consent for study-required photography and adherence to photography requirements. * Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure. * Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at Visit 1. Exclusion Criteria: * Presence of an active systemic disease that may affect wound healing. * Prominent telangiectases in the area(s) to be treated. * History of post-inflammatory hyperpigmentation. * Papulopustular or Phymatous Rosacea. * Severe solar elastosis. * Significant scarring in area(s) to be treated. * Open wounds or lesions in the area(s) to be treated. * Severe or cystic acne on the area(s) to be treated. * Presence of a metal stent or implant in the area(s) to be treated. * Inability to understand the protocol or to give informed consent. * Microdermabrasion, or prescription level glycolic acid treatments to the intended treatment area(s) within six weeks prior to study participation or during the study. * Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area(s) to be treated. * History of chronic drug or alcohol abuse. * History of autoimmune disease. * Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device. * Subjects who anticipate the need for surgery or overnight hospitalization during the study. * Subjects who, in the investigator's opinion, have a history of poor cooperation,noncompliance with medical treatment, or unreliability. * Concurrent enrollment in any study involving the use of investigational devices or drugs. * Current smoker or history of smoking in the last five years. * History of the following cosmetic treatments in the area(s) to be treated: 1. Skin tightening procedure within the past year; 2. Injectable filler of any type within the past: * 12 months for Hyaluronic acid fillers (e.g.,Restylane) * 12 months for Ca Hydroxyapatite fillers (e.g., Radiesse) * 24 months for Poly-L-Lactic acid fillers (e.g., Sculptra) * Ever for permanent fillers (e.g., Silicone, ArteFill) 3. Neurotoxins within the past three months; 4. Ablative resurfacing laser treatment; 5. Nonablative, rejuvenative laser or light treatment within the past six months; 6. Surgical dermabrasion or deep facial peels * History of using the following prescription medications: 1. Accutane or other systemic retinoids within the past six months; 2. Topical Retinoids within the past two weeks; 3. Antiplatelet agents / Anticoagulants (Coumadin, Heparin, Plavix); 4. Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing informed consent.